Alpesh Dalal

So as far as the growth momentum is concerned, as we have regularly been saying, we may not be able to provide guidance for the future. But as a general rule or the way we have been working at various aspects and the way we are developing our pipeline, we can visualize a very healthy and steady growth.

And to answer your second question, what could be the challenges that we could face or what could slow down our growth? Proba bly -- see, the thing is the regulatory pathway in pharmaceutical industry is a very critical aspect. Whilst we are working towards being very robust and compliant with our practices, once in a while, the way regulatory authorities look at us could be a bit different.

The Biologics business, from a growth trajectory perspective, should witness significantly higher growth, purely because it's on a smaller base and a lot of the future lies on the Biologics side. Again, I would reiterate that we would not be in a position to p rovide exact numbers, the kind of growth and all because we don't provide that kind of a guidance.